Development of an economic model to evaluate the burden of myelodysplastic syndromes over 5 years. Results are obtained in terms of cost and clinical benefit in transfusion-dependent and transfusion-independent patients.
This website uses cookies so that we can offer you the best possible user experience. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team understand which sections of the website you find most interesting and useful.